As of 2024-12-14, the EV/EBITDA ratio of Biomarin Pharmaceutical Inc (BMRN) is 25.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Biomarin's latest enterprise value is 12,928.79 mil USD. Biomarin's TTM EBITDA according to its financial statements is 516.55 mil USD. Dividing these 2 quantities gives us the above Biomarin EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.7x - 17.5x | 16.0x |
| Forward P/E multiples | 18.2x - 33.4x | 25.5x |
| Fair Price | 29.89 - 56.26 | 42.08 |
| Upside | -54.9% - -15.1% | -36.5% |
| Date | EV/EBITDA |
| 2024-12-11 | 24.92 |
| 2024-12-10 | 25.09 |
| 2024-12-09 | 25.23 |
| 2024-12-06 | 25.21 |
| 2024-12-05 | 24.99 |
| 2024-12-04 | 25.12 |
| 2024-12-03 | 23.90 |
| 2024-12-02 | 24.58 |
| 2024-11-29 | 24.94 |
| 2024-11-27 | 24.72 |
| 2024-11-26 | 24.52 |
| 2024-11-25 | 24.60 |
| 2024-11-22 | 24.29 |
| 2024-11-21 | 23.99 |
| 2024-11-20 | 23.66 |
| 2024-11-19 | 23.45 |
| 2024-11-18 | 23.43 |
| 2024-11-15 | 23.98 |
| 2024-11-14 | 24.79 |
| 2024-11-13 | 25.18 |
| 2024-11-12 | 24.98 |
| 2024-11-11 | 25.07 |
| 2024-11-08 | 25.33 |
| 2024-11-07 | 25.28 |
| 2024-11-06 | 24.99 |
| 2024-11-05 | 24.95 |
| 2024-11-04 | 24.94 |
| 2024-11-01 | 25.15 |
| 2024-10-31 | 24.89 |
| 2024-10-30 | 25.18 |
| 2024-10-29 | 26.38 |
| 2024-10-28 | 26.46 |
| 2024-10-25 | 26.31 |
| 2024-10-24 | 26.55 |
| 2024-10-23 | 26.40 |
| 2024-10-22 | 26.60 |
| 2024-10-21 | 26.51 |
| 2024-10-18 | 26.45 |
| 2024-10-17 | 26.21 |
| 2024-10-16 | 26.47 |
| 2024-10-15 | 26.58 |
| 2024-10-14 | 26.51 |
| 2024-10-11 | 26.54 |
| 2024-10-10 | 26.35 |
| 2024-10-09 | 26.34 |
| 2024-10-08 | 25.93 |
| 2024-10-07 | 26.03 |
| 2024-10-04 | 26.23 |
| 2024-10-03 | 25.73 |
| 2024-10-02 | 26.28 |